Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function ...

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...

Exposure to any germs could've killed her. 11 years later, she's living a normal life ...

New research found that gene therapy for children with "bubble boy disease," or SCID, was successful in 95% of trial participants.